S0758
磺胺苯吡唑
≥98%, CYP2C9 inhibitor, powder
别名:
4-氨基-N-(1-苯基-1H-吡唑-5-基)苯磺酰胺
Product Name
磺胺苯吡唑, ≥98%
质量水平
方案
≥98%
表单
powder
溶解性
ethanol: 25 mg/mL, clear, colorless to yellow
储存温度
2-8°C
SMILES字符串
Nc1ccc(cc1)S(=O)(=O)Nc2ccnn2-c3ccccc3
InChI
1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2
InChI key
QWCJHSGMANYXCW-UHFFFAOYSA-N
基因信息
human ... CYP2C18(1562), CYP2C19(1557), CYP2C9(1559)
正在寻找类似产品? 访问 产品对比指南
应用
磺胺苯吡唑已用作定量分析红景天提取物对细胞色素P450 2C9(cyp2c9)抑制作用的阳性对照。也用作内皮细胞和微粒体制品中的细胞色素P450 2C9 (cyp2c9)抑制剂。
生化/生理作用
抗细菌。CYP2C9的特异性抑制剂。阻断由CYP2C9介导的亚油酸（氧化应激和AP-1活化增加）的促炎症和致动脉粥样硬化作用。CYP2C9的特异性抑制剂。阻断由CYP2C9介导的亚油酸（氧化应激和AP-1活化增加）的促炎症和致动脉粥样硬化作用。抑制缓激肽诱导的tPA释放。
储存分类代码
11 - Combustible Solids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform
Moraes CB, et al.
SLAS discovery, 24(3), 346-361 (2019)
Noncompetitive inhibition of human CYP 2C9 in vitro by a commercial Rhodiola rosea product
Thu OKF, et al.
Pharmacology Research & Perspectives, 5(4), e00324-e00324 (2017)
Ralf Heim et al.
Journal of medicinal chemistry, 51(16), 5064-5074 (2008-08-05)
Recently, we reported on the development of potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. A major drawback of these nonsteroidal compounds was a strong inhibition of the hepatic drug-metabolizing
Simon Lucas et al.
Journal of medicinal chemistry, 54(7), 2307-2319 (2011-03-10)
Pyridine substituted 3,4-dihydro-1H-quinolin-2-ones (e.g., 1-3) constitute a class of highly potent and selective inhibitors of aldosterone synthase (CYP11B2), a promising target for the treatment of hyperaldosteronism, congestive heart failure, and myocardial fibrosis. Among these, ethyl-substituted 3 possesses high selectivity against
Zhiping Jin et al.
Basic & clinical pharmacology & toxicology, 130(5), 592-605 (2022-03-16)
Anlotinib is a small molecule of novel tyrosine kinase inhibitor initially approved to treat non-small cell lung cancer in China. Drug-drug interaction (DDI) is an extrinsic factor important for the appropriate use of anlotinib in clinical practice. In vitro experiments
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持